ROCKVILLE, Md., Sept. 20 /PRNewswire/ -- Protiveris Inc., a company commercializing microcantilever technologies to facilitate academic research and drug discovery, today announced the appointment of Mr. Julian Abery as Vice President, Business Development. Mr. Abery will be charged with oversight of the company's business development, marketing and sales operations.
"I am very pleased to welcome Julian to the Protiveris management team," said Robert Menzi, Chief Operating Officer at Protiveris. "His considerable experience in bringing new technologies to the market and driving revenue growth will complement our current strengths and significantly contribute to the successful commercialization of our microcantilever technology."
Mr. Abery brings to Protiveris a strong business and technical background, with 25 years of bio-industry experience gained in both scientific and commercial roles. Prior to joining Protiveris, Mr. Abery held the position of Vice President and Head of Business Unit for Biacore A.B., Sweden, where he was responsible for the successful expansion of the company's business into the pharmaceutical and biotechnology markets. Mr. Abery also held various scientific and management positions at the UK based drug discovery company Xenova Discovery Ltd. and its JV with technology supplier EG&G Wallac (now a part of Perkin Elmer Corporation). Mr. Abery received a BSc in Clinical Biochemistry and earned his Masters Degree in Analytical Chemistry from the University Of Greenwich, London, UK.
About Protiveris, Inc.
Protiveris Inc. is the world's leading technology company dedicated to the commercialization of micro- and nano-cantilever systems for academic research, drug discovery and development, bio-defense and diagnostic applications. The Company's first product, the VeriScan(TM)3000 and associated micro-cantilever array chips, deliver label-free, real-time data to provide unique insights into the interactions of a wide range of compounds and biological substances, including polymers, antibodies, proteins, cells, viruses and drug candidates. Protiveris aims to become the pre-eminent global supplier of label-free technology to the academic research and drug discovery markets, by providing a technology platform that can deliver unique, high-value data. In addition, Protiveris will look to address the clinical diagnostics and bio-defense markets through strategic alliances and collaborations with government agencies.
Protiveris is a privately held company based in Rockville, Maryland, USA.
Further information on Protiveris can be found at the company's web site at http://www.protiveris.com.
For further information regarding this press release, please contact:
Chief Operating Officer
Phone: 301-738-7800 Ext. 104